Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib pharmacokinetics and pharmacodynamics in hepatocellular carcinoma with Child-Pugh B cirrhosis
NL-OMON44524Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Amsterdam University Medical Center. Primary endpoints: Sorafenib exposure and variability and Predictive factors for sorafenib exposure. Started Jul 2014; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON44524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44524.